CompletedNCT05930509
Home-based Non-invasive Brain Stimulation for Treatment-resistant Depression Feasibility, Efficacy and Biomarker of Treatment Response
Device studyAges 18+Spain
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- BarcelonaSee all locations and recruitment
Study information
Study start dateStarted: June 15, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Institut Guttmann
- Sponsor type
- Research institute
- Study type
- Device
- Intervention type
- DEVICE
- Study phase
- Not clearly listed
- Locations
- Spain
- Age range
- Over 18 Years
- Official registry ID
- NCT05930509
- Official title
Show the full official title
Home-based Non-invasive Brain Stimulation for Treatment-resistant Depression: Feasibility, Efficacy and Biomarker of Treatment Response
Recruitment & locations
CompletedBarcelona
Questions about this study
Who is behind this study?
The study sponsor is Institut Guttmann, a research institute.
Who was this study for?
Listed age limits: from 18 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide